Tempus is one of those rare companies that you just want to stand back and literally watch them change the face of healthcare. While many companies, especially startups in the healthcare industry, seem to come and go, big things are on the horizon for Tempus. The startup is seeking to help physicians develop better crafted and more customized cancer treatments utilizing a streamlined operations system that houses genome and clinical data. Sounds like a mouthful, huh?
Genomic data is unique to each person and is highly valuable when creating a cancer treatment plan. The cost of gathering genomic data has dropped significantly in past years and Tempus wants to pivot off of that fact to gather genomic data from as many cancer patients as possible and then house them into one system. This system would be digitized and every patient with cancer would then benefit from the data that has been collected. Physicians could develop more customized treatments and would have instant access to that world of data and more information click here.
Data is key to Tempus. The company focuses on the collection and use of data in helping physicians provide cancer treatments.
It’s no surprise that this company was founded by Eric Lefkofsky. He is a jack of all trades when it comes to developing and funding companies in the tech sector that succeed thanks to the power of data. His past business ventures include founding Groupon and Uptake Technologies (valued at $2 billion and rising) and learn more about Eric.
Lefkofsky is a spirited entrepreneur and is known for taking the side of disruptive companies and ideas to help use technology to solve current issues. He is a creator of many startups that have gone on to become household names and “innovative” is the word best used to describe him and Eric’s lacrosse camp.
Tempus is not just a vision for changing the face of cancer treatment, it is coming to full fruition. Recent partnerships with the Mayo Clinic and the Cleveland Clinic are making Lefkofsky’s vision a reality and allowing Tempus to work on collecting data.
The company recently announced that it has raised an additional $70 million dollars in its Series C funding round, bringing total funding to $130 million and forging these partnerships ahead and https://www.tempus.com/about-us/.